NewsStackNewsStack
Daily Brief: Which companies are hyping vs delivering: red flags, real signals and repeat offenders, free daily.

BIIB

NASDAQ:BIIBNASDAQ
16 announcements
Credibility Score66%
Clarity AD CSF Substudy Findings on Lecanemab Treatment and α-Synuclein Co-Pathology Presented at CTAD 2026
Overhypedunclear

Lecanemab shows strong efficacy in early Alzheimer’s, especially for patients with α-Syn co-pathology.

19 Nov 2026, 18:35 UTC
▼
New Three-Year Real-World LEQEMBI® Data Presented at CTAD 2026
Overhypedunclear

LEQEMBI shows strong real-world durability and safety in early Alzheimer's across 560 U.S. patients.

18 Nov 2026, 16:00 UTC
▼
ACR 2026: Dapirolizumab Pegol Associated with Greater Treatment Response Rates Versus Placebo in SLE Using Novel Treatment Response Measure
OverhypedModerate hypeunclear

Biogen and UCB’s lupus drug shows strong Phase 3 efficacy, but remains unapproved and long-dated.

9 Nov 2026, 06:00 UTC
▼
LEQEMBI IQLIK®(lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer's Disease
OverhypedModerate hypeunclear

Biogen launches at-home Alzheimer's injection, but financial impact remains unquantified.

24 Aug 2026, 12:05 UTC
▼
Biogen Appoints Michael J. Parini as Chief Legal Officer
Routineunclear

This is a routine executive hire with no immediate investment impact or financial disclosure.

15 Jul 2026, 12:27 UTC
▼
14 Jul 2026, 15:28 UTC
▼
Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease
OverhypedModerate hypeunclear

Biogen’s Alzheimer’s drug shows promise, but commercial payoff is years and risks away.

14 Jul 2026, 13:29 UTC
▼
Block & Leviton LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Common Stock of Biogen, Inc. – BIIB
Routineunclear

This is a routine legal settlement, not a signal of business strength or weakness.

29 Jun 2026, 12:12 UTC
▼
Biogen to Highlight Breadth of Alzheimer’s Disease Portfolio at AAIC 2026, Including Phase 2 CELIA Data for Diranersen
OverhypedModerate hypeunclear

Biogen touts Alzheimer’s progress, but offers little hard data or near-term financial clarity.

29 Jun 2026, 11:15 UTC
▼
Biogen’s Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy
OverhypedModerate hypeunclear

Biogen’s SMA drug gets FDA boost, but real proof and profits are years away.

4 Jun 2026, 11:45 UTC
▼
EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus
OverhypedModerate hypeunclear

Biogen’s lupus drug shows promise, but real investor payoff is still years away.

4 Jun 2026, 05:08 UTC
▼
Biogen Announces Upcoming Kidney Presentations at European Renal Association and American Transplant Congresses
OverhypedModerate hypeunclear

Biogen’s nephrology update is clinically solid but offers little for investors seeking financial clarity.

3 Jun 2026, 11:42 UTC
▼
UCB and Biogen Announce Publication in The Lancet of Positive Dapirolizumab Pegol (DZP) Phase 3 Study Results in Systemic Lupus Erythematosus
OverhypedModerate hypeunclear

Promising clinical data, but commercial payoff is distant and far from guaranteed.

1 Jun 2026, 05:36 UTC
▼
Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease
Weak Signalunclear

Biogen and Denali’s Parkinson’s drug failed, and the program is being shut down.

21 May 2026, 22:08 UTC
▼
Biogen Completes Acquisition of Apellis Pharmaceuticals
OverhypedModerate hypeunclear

Biogen’s Apellis buy adds revenue, but future gains are mostly unproven and years away.

14 May 2026, 12:46 UTC
▼
Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer's Disease
OverhypedModerate hypeunclear

Regulatory progress is real, but commercial impact and timelines remain highly uncertain.

8 May 2026, 06:40 UTC
▼